CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Cardinal Health lifts 2025 profit forecast on specialty drugs demand
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expiration GAAP 1 operating earnings were $549 million; GAAP...
Cardinal Health to Report Q2 Earnings: What's in Store for the Stock?
Despite recent supply-chain challenges, new facilities and growth in branded and specialty pharmaceutical sales are likely to have driven CAH's performance in the fiscal second quarter.
Cardinal Health Stock May Gain With New Texas Distribution Center
CAH announces the ongoing construction of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Cardinal Health (CAH) Increases Yet Falls Behind Market: What Investors Need to Know
In the latest trading session, Cardinal Health (CAH) closed at $124.71, marking a +0.55% move from the previous day.
Cardinal Health, Inc. (CAH) CEO Jason Hollar presents at J.P. Morgan Healthcare Conference (Transcript)
Cardinal Health, Inc. (NYSE:CAH ) J.P. Morgan Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Aaron Alt - CFO Jason Hollar - CEO Conference Call Participants Lisa Gill - JPM...
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Reasons to Add Cardinal Health Stock to Your Portfolio Now
CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.
Canada Personal Protective Equipment Market Outlook to 2033 Featuring Cardinal Health, Medline Industries, and 3M
Dublin, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The "Canada Personal Protective Equipment Market Outlook to 2033 - Gloves, Gowns, Masks, Shoe Covers and Others" report has been added to ResearchAndMarket...
Cardinal Health (CAH) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Cardinal Health (CAH) reachead $118.83 at the closing of the latest trading day, reflecting a +0.41% change compared to its last close.
Strength Across Segments to Help CAH Stock Offset OptumRx Headwind?
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, concentrated revenue generation and regulatory setbacks are a concern.
Cardinal Health, Inc. (CAH) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Cardinal Health, Inc. (NYSE:CAH ) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 1:30 PM ET Company Participants Matt Sims - VP, IR Aaron Alt - CFO Conference Call Participan...
Cardinal Health, Inc. (CAH) UBS Global Healthcare Conference (Transcript)
Cardinal Health, Inc. (NYSE:CAH ) UBS Global Healthcare Conference November 12, 2024 11:00 AM ET Company Participants Matt Sims - Vice President, Investor Relations Aaron Alt - Chief Financial Offi...
Related Companies